GoodRx (NASDAQ:GDRX – Get Rating) had its target price upped by The Goldman Sachs Group from $9.00 to $10.00 in a report released on Tuesday, The Fly reports. The firm currently has a neutral rating on the stock.
GDRX has been the topic of several other research reports. Cowen dropped their price target on shares of GoodRx from $22.00 to $9.00 and set a market perform rating on the stock in a research note on Monday, June 13th. Morgan Stanley dropped their price target on shares of GoodRx from $19.00 to $10.50 and set an equal weight rating on the stock in a research note on Friday, May 20th. SVB Leerink lowered shares of GoodRx from an outperform rating to a market perform rating and dropped their price target for the company from $33.00 to $10.00 in a research note on Tuesday, May 10th. Guggenheim dropped their price target on shares of GoodRx from $17.00 to $13.00 and set a buy rating on the stock in a research note on Monday, July 18th. Finally, Cowen decreased their price objective on shares of GoodRx from $22.00 to $9.00 in a report on Monday, June 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $16.37.
Get GoodRx alerts:GoodRx Price Performance
GDRX opened at $7.60 on Tuesday. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of -69.09, a price-to-earnings-growth ratio of 22.62 and a beta of 0.77. GoodRx has a fifty-two week low of $5.61 and a fifty-two week high of $48.05. The company's 50-day moving average price is $6.59 and its 200 day moving average price is $13.75. The company has a quick ratio of 16.76, a current ratio of 11.23 and a debt-to-equity ratio of 0.80.
GoodRx (NASDAQ:GDRX – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. GoodRx had a negative net margin of 5.86% and a positive return on equity of 2.97%. The company had revenue of $191.80 million for the quarter, compared to analyst estimates of $184.71 million. During the same quarter last year, the business earned $0.08 earnings per share. GoodRx's revenue was up 8.6% compared to the same quarter last year. As a group, sell-side analysts expect that GoodRx will post 0.02 earnings per share for the current year.Institutional Trading of GoodRx
A number of large investors have recently added to or reduced their stakes in GDRX. Janney Montgomery Scott LLC boosted its holdings in GoodRx by 69.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 26,696 shares of the company's stock worth $872,000 after buying an additional 10,980 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in GoodRx by 226.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 22,993 shares of the company's stock worth $751,000 after purchasing an additional 15,944 shares during the period. CWM LLC acquired a new position in GoodRx in the 4th quarter worth approximately $48,000. Qube Research & Technologies Ltd acquired a new position in GoodRx in the 4th quarter worth approximately $706,000. Finally, DekaBank Deutsche Girozentrale boosted its stake in GoodRx by 438.5% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 70,000 shares of the company's stock worth $2,248,000 after purchasing an additional 57,000 shares during the period. 52.60% of the stock is currently owned by institutional investors.
GoodRx Company Profile
(Get Rating)
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
Featured Articles
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.